Senior Director, Pharmacometrics

Company Overview

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; and IM-3050, a clinical-stage FAP-targeted radioligand therapy. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.

Position Overview

Immunome is seeking a highly experienced and strategic Senior Director, Pharmacometrics to lead model-informed drug development strategies across Immunome’s targeted oncology portfolio. This role will be responsible for the design, execution, interpretation, and communication of pharmacometric analyses that support clinical development decisions, dose selection and optimization, regulatory submissions, and product labeling.

The successful candidate will bring deep technical expertise in population PK, PK/PD, exposure-response, simulation, and fit-for-purpose application of PBPK, QSP, or other quantitative modeling approaches. This position offers a highly visible leadership opportunity to shape Immunome’s pharmacometrics strategy, influence program and portfolio decisions, and advance innovative oncology therapeutics from early clinical development through registration and lifecycle management.

Responsibilities

Strategic Leadership

• Develop and implement pharmacometrics strategies across clinical development programs, ensuring quantitative approaches are aligned with program objectives , clinical pharmacology plans, and regulatory expectations.

• Serve as the pharmacometrics strategy lead for assigned programs, providing scientific leadership for dose selection, dose optimization, exposure-response assessment, and model-informed decision-making.

• Contribute to the long-term vision for Immunome’s quantitative clinical pharmacology capabilities, including standards for modeling, simulation, documentation, and cross-functional integration.

Modeling, Simulation, and Quantitative Strategy

• Lead the development and execution of population PK, PK/PD, exposure-response, disease progression, and model-based meta-analysis strategies to support clinical development and registration. </ul&gt